

**CLEARBRIDGE HEALTH LIMITED**  
(Company Registration No. 201001436C)  
(the "**Company**")

---

**PROPOSED ACQUISITION OF SHARES IN PT INDO GENESIS MEDIKA – COMPLETION OF THE  
SUBSCRIPTION OF REDEEMABLE EXCHANGEABLE BOND**

---

*Unless otherwise defined herein or the context otherwise requires, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Company's announcements dated 23 August 2018, 13 November 2018, 3 April 2019, 8 April 2019 and 7 May 2019 in relation to the Proposed Transactions.*

The Board is pleased to announce the completion of the subscription of the REB (the "**REB Subscription**") on 24 June 2019. In connection with the REB Subscription, a pledge over the REB Exchange Shares has been created in favour of SAM Laboratory Pte. Ltd. ("**SAM**") as security for the REB.

As announced on 3 April 2019, completion of the REB Subscription is conditional upon, among other things, the completion of the novation of 11 JO Contracts to PT Indo Genesis Medika (the "**Target**"), (the "**REB Subscription Condition**"). As of 24 June 2019, nine (9) JO Contracts have been validly and legally novated to the Target with the novation of the remaining two (2) JO Contracts (the "**Remaining JO Contracts**") currently in progress.

As the novation of the Remaining JO Contracts may require more time, SAM has agreed to waive full compliance with the REB Subscription Condition (the "**REB Subscription Waiver**"), in view of the fact that the Target now holds approximately 98% of the value of the 11 JO Contracts.

In connection with the REB Subscription Waiver, the parties have entered into (1) a supplemental deed to amend the terms of the REBSA to, among others, allow for the completion of the REB Subscription on the date of the REB Subscription Waiver; and (2) a supplemental deed to amend the terms of the SPA to, among others, (a) adjust the second tranche of the Consideration to IDR7.5 billion (approximately S\$0.7 million<sup>1</sup>) payable by SAM to KPN for the nine (9) JO Contracts that have been validly and legally novated to the Target; and (b) adjust the third tranche of the Consideration to IDR11.9 billion (approximately S\$1.1 million<sup>1</sup>) payable by SAM to KPN within five (5) business days of the date on which the remaining three (3) JO Contracts are validly and legally novated to the Target, or such other date as the parties may agree in writing. For the avoidance of doubt, there is no change to the Consideration for the Sale Shares of IDR54.0 billion (approximately S\$5.1 million<sup>1</sup>).

Accordingly, the adjusted second tranche of the Consideration has been paid by SAM to KPN. Separately, the REB Issue Price of IDR22.0 billion (approximately S\$2.1 million<sup>1</sup>) has also been paid by SAM to KPN.

---

<sup>1</sup>All conversions of IDR to S\$ in this announcement are based on an exchange rate of S\$1:IDR10,500.

A copy of each of the supplemental deeds is available for inspection at the registered address of the Company for a period of three (3) months from the date of this announcement.

The Company will make further announcements as and when there are further material updates and developments in respect of the Proposed Transactions.

**BY ORDER OF THE BOARD**

Yee Pinh Jeremy  
Chief Executive Officer and Executive Director

24 June 2019

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*